These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 29504894)
1. Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients. Yang IS; Kim S BMC Bioinformatics; 2018 Feb; 19(Suppl 1):40. PubMed ID: 29504894 [TBL] [Abstract][Full Text] [Related]
2. SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysis. Liu L; Ahmed T; Petty WJ; Grant S; Ruiz J; Lycan TW; Topaloglu U; Chou PC; Miller LD; Hawkins GA; Alexander-Miller MA; O'Neill SS; Powell BL; D'Agostino RB; Munden RF; Pasche B; Zhang W Mol Oncol; 2021 Feb; 15(2):462-472. PubMed ID: 33107184 [TBL] [Abstract][Full Text] [Related]
3. YTHDF1 Promotes Cyclin B1 Translation through m Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W Cells; 2021 Jul; 10(7):. PubMed ID: 34359836 [TBL] [Abstract][Full Text] [Related]
4. The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features. Ma Z; Zhang Y; Deng C; Fu F; Deng L; Li Y; Chen H J Thorac Cardiovasc Surg; 2022 Jan; 163(1):e73-e85. PubMed ID: 32739163 [TBL] [Abstract][Full Text] [Related]
5. A cross-sectional study examining the expression of splice variants K-RAS4A and K-RAS4B in advanced non-small-cell lung cancer patients. Aran V; Masson Domingues P; Carvalho de Macedo F; Moreira de Sousa CA; Caldas Montella T; de Souza Accioly MT; Ferreira CG Lung Cancer; 2018 Feb; 116():7-14. PubMed ID: 29413054 [TBL] [Abstract][Full Text] [Related]
6. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma. Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432 [TBL] [Abstract][Full Text] [Related]
7. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650 [TBL] [Abstract][Full Text] [Related]
8. Inhibitor of Differentiation-1 Sustains Mutant Román M; López I; Guruceaga E; Baraibar I; Ecay M; Collantes M; Nadal E; Vallejo A; Cadenas S; Miguel ME; Jang JH; Martin-Uriz PS; Castro-Labrador L; Vilas-Zornoza A; Lara-Astiaso D; Ponz-Sarvise M; Rolfo C; Santos ES; Raez LE; Taverna S; Behrens C; Weder W; Wistuba II; Vicent S; Gil-Bazo I Cancer Res; 2019 Feb; 79(3):625-638. PubMed ID: 30563891 [TBL] [Abstract][Full Text] [Related]
10. Weighted gene coexpression network analysis identifies hub genes related to KRAS mutant lung adenocarcinoma. Dai D; Shi R; Han S; Jin H; Wang X Medicine (Baltimore); 2020 Aug; 99(32):e21478. PubMed ID: 32769881 [TBL] [Abstract][Full Text] [Related]
11. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy. Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290 [TBL] [Abstract][Full Text] [Related]
12. Aberrant S100A16 expression might be an independent prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma. Chen D; Luo L; Liang C PLoS One; 2018; 13(5):e0197402. PubMed ID: 29746588 [TBL] [Abstract][Full Text] [Related]
13. KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma. Nadal E; Chen G; Prensner JR; Shiratsuchi H; Sam C; Zhao L; Kalemkerian GP; Brenner D; Lin J; Reddy RM; Chang AC; Capellà G; Cardenal F; Beer DG; Ramnath N J Thorac Oncol; 2014 Oct; 9(10):1513-22. PubMed ID: 25170638 [TBL] [Abstract][Full Text] [Related]
14. USP4 expression independently predicts favorable survival in lung adenocarcinoma. Zhong M; Jiang Q; Jin R IUBMB Life; 2018 Jul; 70(7):670-677. PubMed ID: 29667299 [TBL] [Abstract][Full Text] [Related]
15. Effects of different KRAS mutants and Ki67 expression on diagnosis and prognosis in lung adenocarcinoma. Wang J; Dong L; Zheng Z; Zhu Z; Xie B; Xie Y; Li X; Chen B; Li P Sci Rep; 2024 Feb; 14(1):4085. PubMed ID: 38374309 [TBL] [Abstract][Full Text] [Related]
17. Non-terminal respiratory unit type lung adenocarcinoma has three distinct subtypes and is associated with poor prognosis. Sumiyoshi S; Yoshizawa A; Sonobe M; Kobayashi M; Sato M; Fujimoto M; Tsuruyama T; Date H; Haga H Lung Cancer; 2014 Jun; 84(3):281-8. PubMed ID: 24725383 [TBL] [Abstract][Full Text] [Related]
18. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma. Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967 [TBL] [Abstract][Full Text] [Related]
19. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies. Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089 [TBL] [Abstract][Full Text] [Related]
20. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma. Xu XL; Gong Y; Zhao DP Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]